$CBIO

Catalyst Biosciences Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$1.97 ▲2.073%

Extented Hours

VOLUME

156,866

DAY RANGE

1.89 - 1.94

52 WEEK

0.3501 - 5.2

Join Discuss about CBIO with like-minded investors

profile
@maletone #StockTraders.NET
recently

$GOVX, $CBIO, $SIGA for me

52 Replies 12 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

watchlist: $GOVX, $BTTX, $CBio, $ELEV

93 Replies 8 👍 13 🔥

profile
@maletone #StockTraders.NET
recently

watch list $GOVX $RDBX, $CBIO for shorts

40 Replies 7 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

covered some more $CBIO

45 Replies 10 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

come on $CBIO do it

117 Replies 8 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

covered some $Cbio

99 Replies 6 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

$cbio close

142 Replies 8 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

I'm short $CBIO

109 Replies 12 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

IF $CBIO goes parabolic might short

86 Replies 6 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

$cbio looks interesting

99 Replies 14 👍 13 🔥

Key Metrics

Market Cap

60.44 M

Beta

1.55

Avg. Volume

335.77 K

Shares Outstanding

31.48 M

Yield

0%

Public Float

0

Next Earnings Date

Next Dividend Date

Company Information

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Its complement pipeline includes a pre-clinical C3-degrader program partnered with Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development.

CEO: Nassim Usman

Website:

HQ: 611 Gateway Blvd Ste 710 South San Francisco, 94080-7029 California

Related News